Silencing of hepatic fate-conversion factors induce tumorigenesis in reprogrammed hepatic progenitor-like cells by Felipe Serrano et al.
RESEARCH Open Access
Silencing of hepatic fate-conversion factors
induce tumorigenesis in reprogrammed
hepatic progenitor-like cells
Felipe Serrano1,4, Maria García-Bravo2, Marina Blazquez1, Josema Torres3, Jose V. Castell1, Jose C. Segovia2
and Roque Bort1*
Abstract
Background: Several studies have reported the direct conversion of mouse fibroblasts to hepatocyte-like cells with
different degrees of maturation by expression of hepatic fate-conversion factors.
Methods: We have used a combination of lentiviral vectors expressing hepatic fate-conversion factors with Oct4,
Sox2, Klf4, and Myc to convert mouse embryonic fibroblasts into hepatic cells.
Results: We have generated hepatic cells with progenitor-like features (iHepL cells). iHepL cells displayed basic
hepatocyte functions but failed to perform functions characteristic of mature hepatocytes such as significant Cyp450 or
urea cycle activities. iHepL cells expressed multiple hepatic-specific transcription factors and functional genes characteristic
of immature hepatocytes and cholangiocytes, as well as high levels of Foxl1, Cd24a, and Lgr5, specific markers of hepatic
progenitor cells. When transplanted into partial hepatectomized and hepatic irradiated mice, they differentiated into
hepatocytes and cholangiocytes. However, iHepL cells formed malignant non-teratoma cell aggregations in one out of
five engrafted livers and five out of five xenografts assays. All the cells in these tumors had silenced key hepatic
fate-conversion factors, and lost hepatic features.
Conclusions: This study highlights the dangers of using pluripotency factors in reprogramming strategies when
fate-conversion factors are silenced in vivo, and urges us to perform extensive tumorigenic tests in reprogrammed cells.
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Background
Overexpression of lineage-specific transcription factors
directly converts fibroblasts into other cell types such as
neurons [1], cardiomyocytes [2], blood progenitors [3], or
hepatocytes [4–7]. Hepatocyte-like cells obtained in differ-
ent reports, either by direct conversion of fibroblasts or
indirectly by differentiation of induced pluripotent stem
cells (iPSC), display a wide range of drug-metabolizing
genes as well as genes involved in hepatocyte metabolic
functions, reflecting a wide variety of maturation [8].
On the other hand, terminally differentiated cells cannot
proliferate in vitro, limiting their utility in biotechnology
and regenerative medicine [1, 4, 5]. Thus, we have focused
on reprogramming fibroblasts into expandable progenitor
cells capable of differentiating into different cell types
within the same lineage. We reasoned that concomitant
expression of Oct4, Sox2, Klf4, and Myc (OSKM) together
with cell fate-converting transcription factors could main-
tain cells in a stem-like fashion allowing their proliferation
and differentiation when exposed to the appropriate extra-
cellular cues. In fact, induced hepatic stem cells (iHepSC)
generated from mouse fibroblasts are phenotypically
closer to fetal hepatocytes than mature hepatocytes, and
they only achieve full maturation after transplantation into
FRG mice [9]. Having stated the advantages of reprogram-
ming into progenitor-like cells, it should also be
highlighted that inclusion of Myc in reprogramming cock-
tails boost reprogramming, but increases the possibility of
obtaining cells prone to tumorigenicity.
* Correspondence: bort_ber@gva.es
1Unidad de Hepatología Experimental, Instituto de Investigación Sanitaria La
Fe, CIBERehd, Avda. Fernando Abril Martorell 106, 46026 Valencia, Spain
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Serrano et al. Stem Cell Research & Therapy  (2016) 7:96 
DOI 10.1186/s13287-016-0349-5
In our study, we have obtained bipotential hepatic
progenitor-like (iHepL) cells by expression of repro-
gramming factors together with hepatic fate-conversion
factors. We selected Hnf4a, Hnf1a, and Foxa2 since they
act coordinately to control multiple aspects of hepato-
cyte differentiation, liver development, and function
[10]. Hhex is expressed in the early hepatic endoderm
during liver development in mice [11]. Gata factors are
crucial for competency of the definitive endoderm [12],
and Hnf6a absence results in premature differentiation
of biliary cells [13]. Our iHepL cells do not express
pluripotency markers, but they express high levels of
two hepatic progenitor-specific genes, Foxl1 and Cd24a
[14, 15], as well as markers of ductal cells. When trans-
planted in vivo, those progenitor cells are able to differ-
entiate into hepatocytes and cholangiocytes. However,
the cells form tumors in xenograft assays when hepatic
fate-conversion factors are spontaneously silenced.
Methods
Cell media and imaging
Mouse embryonic fibroblasts (MEF) were prepared from
13.5-day post-coitum embryos. MEF were grown in
DMEMc (Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10 % fetal bovine serum (FBS) and
2 mM Glutamax). In the reprogramming experiments
two different media were used: hepatocyte conditioned
medium (HCM) I and HCM II. HCM I is composed of
IMDM:F12 (1:3), supplemented with 10 % FBS, 2 mML-
glutamine, penicillin/streptomycin, 10 ng/ml epidermal
growth factor (EGF), 100 ng/ml fibroblast growth factor
(FGF)2, 50 ng/ml vascular endothelial growth factor
(VEGF), and 100 ng/ml transforming growth factor
(TGF)β. HCM II is composed of IMDM:F12 (1:3), sup-
plemented with 10 % FBS, 2 mML-glutamine, penicillin/
streptomycin, 10 ng/ml hepatocyte growth factor (HGF),
and 10 ng/ml Oncostatin M. All media was purchased
from Invitrogen (www.thermofisher.com). Growth fac-
tors were purchased from R&D Systems (www.rndsys-
tems.com). iHepL cells exhibited enhanced attachment
to the culture dishes and needed trypsinization for
30 min at 37 °C for passaging.
All cells were maintained at 37 °C with 5 % CO2 and
were regularly examined with an Olympus CKX41
microscope. Images were taken on an Olympus FV1000
confocal mounted on an IX81 inverted microscope.
Plasmids and retrovirus generation
The retroviral constructs pMIGR1-Hhex, pMIGR1-
Hnf1a, and pMIGR1-Hnf6a were generated by polymer-
ase chain reaction (PCR) amplification of the cDNAs
(see Additional file 1: Table S1 for oligo sequence)
followed by subcloning into the XhoI-EcoRI restriction
sites of pMIGR1 [16]. All constructs were verified by
sequencing. pBabe-Foxa2, pBabe-Hnf4a, and pBabe-
Gata4 are derivatives of the pBabe-puro retroviral vector
[17] donated by Dr. Ken Zaret (University of Pennsylva-
nia, Philadelphia, PA, USA). The plasmids encoding the
reprogramming factors pMXs-Oct4, pMXs-Sox2, pMXs-
Klf4, and pMXs-cMyc were purchased from Addgene
(Cambridge, MA, USA; www.addgene.com) [18]. A sum-
mary of the retroviral plasmids is shown in Additional
file 1 (Table S2). Ecotropic retroviruses were generated
in 293 T cells as described elsewhere [19]. MEF were in-
fected with equal volumes of each retrovirus.
Primary hepatocyte isolation and culture
Mice hepatocytes were isolated using a two-step perfusion
technique as previsouly described [20]. Briefly, the liver
was pre-perfused through the portal vein with calcium-
free buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM H2KPO4,
1.2 mM Mg2SO4, 25 mM HNaCO3, 10 mM glucose,
0.5 mM EGTA, pH 7.4) and then perfused with the same
buffer containing 2.5 mM CaCl2 and 125 U/ml collage-
nase IV. Once the enzymatic digestion was completed, the
liver was transferred to a petri dish and the cells were gen-
tly dispersed with a blunt tool. Cells were collected by
low-speed centrifugation. Viability of isolated hepatocytes
was around 90 % as determined by Trypan blue.
iHepL induction
Approximately 106 early passage (passage 2 or 3) MEF
were seeded on a 10-cm dish containing DMEMc. One
day later, cells were infected with indicated viruses sup-
plemented with 4 μg/ml polybrene for 24 h. Seventy two
hours later, media were changed to HCM I and the cul-
ture continued for an additional 18 days. Culture
medium was refreshed every day. Cells were frozen at
this stage at 1.5 × 106 cells per vial to generate cell stocks
for future use. The final differentiation step was achieved
by thawing one vial into a 10-cm dish containing HCM
II media with further culturing for 6 days. Cells should
be split if confluent by using TrypLE™ Select. If needed,
cells can be maintained for longer periods by regular
passaging. Phenotypic characterization of iHepL cells
was performed at confluency. All the data shown in the
paper come from the average of two biological replicates
from each of the three infections.
To obtain isogenic cell clones, cells were seeded at low
density and colonies were transferred to 96-well plates
and expanded. Data depicted in the figures in Additional
file 1 were obtained from two biological replicates from
clone 2 (isolated from infection #1), clone 6 (isolated from
infection #2), and clone 15 (isolated from infection #3).
Reverse transcription and quantitative PCR
Total RNA was extracted using the RNeasy mini kit
(www.qiagen.com) and reverse-transcribed using Moloney
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Murine Leukemia Virus reverse transcriptase (www.ther-
mofisher.com) according to the manufacturer’s protocol.
Genomic DNA was extracted from paraffin-embedded tu-
mors and tissues using the Qiamp DNA FFPE Tissue Kit
(www.qiagen.com). PCR amplification was performed
using the expand high fidelity PCR system (Roche, Basel,
Switzerland; www.lifescience.roche.com) following the
manufacturer’s instructions on a Light Cycler 480 II Real-
Time PCR System using the Light Cycler 480 SYBR Green
I Master. The specificity of the amplified PCR products
was confirmed by analysis of the melting curve and agar-
ose gel electrophoresis. Primers used for the quantitative
PCR (qPCR) are shown in Additional file 1: Tables S3 and
S4. Primers designed to measure endogenously expressed
transcription factors were validated by running a PCR
assay using the corresponding retroviral shuttle plasmids.
The relative expression of each mRNA was normalized
against mouse beta Actin (Actb). The relative gene copy
number in genomic DNA was estimated as described else-
where [21] using a fragment amplified from intron 1 of
Ccnd1for normalization. Primers used to amplify exogen-
ous genes were validated using the corresponding retro-
viral plasmids.
MicroRNA was extracted with an adapted protocol
from Qiagen using the miRNeasy kit which consisted of
precipitating with 1.5 volumes of 100 % ethanol instead
of 1 volume of 70 % ethanol. miR122-specific reverse
transcription stem loop was performed using the primer
5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGC
ACTGGATACGACCAAACA-3′ as described in [22].
qPCR was run using miR-122 specific primers 5′-TT
GGAGCTCCCTTTTTGCTA-3′ and 5′-CACCATGCC
TGGCTAATTTT-3′.
Cell and tissue immunofluorescence
Cells were fixed with 4 % paraformaldehyde at room
temperature, and then washed three times with
phosphate-buffered saline (PBS). Cells were blocked with
blocking buffer (5 % normal donkey serum, 0.3 % Triton
X-100 in PBS) for 60 min at room temperature and then
incubated with primary antibodies at 4 °C overnight in
0.1× blocking buffer. The next day cells were washed
three times with PBS, and then incubated with Alexa
Fluor conjugated secondary antibodies at 1/500 dilution
(Life Technologies) for 60 min at room temperature in
the dark. Nuclei were stained with DAPI (200 ng/ml for
15 min). The high content screening imaging station
Scan® from Olympus was used to analyze the number
and intensity of cell staining. Total cell number was
calculated from the number of DAPI-positive nuclei
(software used).
Sections of the paraffin-embedded tissues were dewaxed
and rehydrated through ethanol:water series and
unmasked by boiling in sodium citrate buffer (10 mM,
pH 6.0, for 10 min). Immunostaining was performed as
described above, but the blocking buffer contained 10 %
normal donkey serum in PBT (0.1 % Tween 20 in PBS).
Slides were mounted with fluorescence mounting media
(Dako). Antibodies used for immunofluorescence staining
are described in Additional file 1 (Table S5).
Flow cytometry
Adherent cells were washed with PBS and detached by
treatment with trypsin (Life Technologies). Cells fixed
with 4 % paraformaldehyde for 10 min at 4 °C were
permeabilized with 90 % methanol for 30 min at 4 °C.
After blocking with 0.5 % ovalbumin, cells were incu-
bated with the primary antibody or normal serum (con-
trol) for 60 min at room temperature. Cells were then
incubated with secondary antibody for 30 min in the
dark. Cells were analyzed by FACSCanto Flow Cyt-
ometer (Becton Dickinson). Nuclei were stained with
DAPI (200 ng/ml in PBS) for 15 min in the dark. Pri-
mary antibodies used for flow cytometry are described in
Additional file 1 (Table S5). To determine the percent-
age of live green fluorescent protein (GFP)-positive cells,
trypsinized cells were resuspended in complete DMEM
containing 50 μg/ml 7-amino actinomycin D (7-AAD)
and incubated for 30 min in the dark. Data were ana-
lyzed using FACSDiva software (Becton Dickinson).
Doublets were eliminated using a pulse geometry gate
(FSC-H x FSC-A).
Indocyanine green uptake, PAS staining, glycogen
depletion, Cyp450 metabolism, and Ugt activity
Confluent cells were incubated with fresh HCM II
medium supplemented with 1 mg/ml indocyanine green
at 37 °C for 30 min. Once pictures were taken, cells were
washed with PBS and cultured in media without indocy-
anine green. Cells were stained by periodic acid-Schiff
(PAS; Sigma) following the manufacturer’s instructions.
To induce glycogen depletion by starvation, iHepL cells
cultured in six-well plates were incubated with Krebs-
Henseleit solution without glucose. Cells were fixed at 0,
1.5, 3, and 6 hours and stained with PAS to estimate
intracellular glycogen content. To induce glycogen de-
pletion with glucagon, cells were incubated in HCM II
media containing 300 ng/ml glucagon.
Cyp450 activities were measured essentially as de-
scribed previously [23]. Briefly, confluent iHepL cells
cultured in six-well plates were incubated in media
containing eight substrates for 4 h at 37 °C. Metabolites
were measured in the supernatant by liquid chromatog-
raphy mass spectrometry (LC-MS/MS). Total cell pro-
tein was used to normalize the data. Isolated primary
hepatocytes and wild-type MEF were used as a positive
and negative control, respectively. Formation of estradiol-
3-glucuronide and estradiol-17-glucuronide was measured
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in cells incubated with β-estradiol 100 μM for 2 h as de-
scribed previously [24].
Cell transplantation into partial hepatectomized and
hepatic irradiated mice
The Animal Care and Ethics Committee from CIEMAT
specifically approved this study (approval number
HEM4-12). The mouse strain used was NSG (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ). Anesthesia was induced by
intraperitoneal injection of a mixture of ketamine
(125 mg/kg) and medetomidine (10 mg/kg). To provide
a proliferative stimulus to hepatic cells, a 45 % partial
hepatectomy (PH) was conducted, removing the right
and left lateral lobules through a transversal midline in-
cision in the abdomen of NSG mice. Immediately after
PH, the animals were placed in a supine position inside
a lead box where a hole was made to allow the localized
irradiation of the median hepatic lobule. Two 3 × 5-cm
lead shields, each 2 mm thick, were fitted under the liver
to protect the stomach and intestines. The liver was irra-
diated using Philips MG324 X-ray equipment (Philips,
Hamburg, Germany) to deliver a dose of 41.05 Gy,
260 kV, 12.3 mA, at a dose rate of 4.105 Gy/min. The
abdomen was then closed in two layers. Anesthesia was
reverted by intraperitoneal injection of atipamezol
(50 mg/kg). Cell transplantation was performed 4 days
after PH and hepatic irradiation. Mice were anesthetized
and the spleen was exposed by a left flank incision.
Homeostasis was achieved by ligation of the splenic tip
using a 2-0 silk suture. To validate our model, 106 hepa-
tocytes freshly isolated by collagenase perfusion of the
liver from ubiquitously expressing mRFP mice were
injected (data not shown). In subsequent experiments,
106 iHepL cells were injected. Three weeks after trans-
plantation, mice were sacrificed and pieces of the liver
were fixed in formalin and histologically evaluated after
paraffin-embedding.
Subcutaneous xenograft animal model
Male, 6- to 8-week-old NSG (NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ) were kept at least 1 week before experimen-
tal manipulation. Cultured iHepL cells (1.5 × 106/injection)
in 150 μl DPBS were implanted subcutaneously in the right
flank region of mice (n = 5). Tumor progression was
followed for up to 6 weeks. Upon sacrifice, primary tumors
were removed, formalin-fixed, and histologically evaluated.
Statistical analysis
All in vitro experiments were conducted a minimum of
three times. Data are expressed as the mean ± standard
deviation. Statistical significance was calculated by un-
paired Student’s t test.
Results
Co-expression of hepatic transcription factors with OSK/M
allows transdifferentiation of MEF to hepatic-like cells
without pluripotent commitment
Considering that reprogramming is a stochastic process,
we reasoned that initial cell reprogramming by expression
of OSK/M could be diverged towards the hepatic cell fate
by co-expressing key determinants of hepatic cell fate
[25]. MEF were infected with retroviral vectors expressing
Gata4, Foxa2, Hnf4a, Hhex, Hnf1a, and Hnf6a, with or
without OSK/M, and cultured with DMEMc for 2 days.
Then, cells were split into two gelatine-coated 10-cm
plates; one plate was maintained in DMEMc and the other
in HCM I containing essential growth factors for mainten-
ance of hepatic lineage. Leukemia inhibitory factor (LIF)
was not included in the reprogramming media to hamper
commitment to the pluripotent fate.
When looking at the reprogramming plates at day 7,
we identify groups of epithelial cells with flattened, en-
larged, and polygonal shapes between fibroblasts (Fig. 1a
and Additional file 1: Figure S1A). The morphology of
iHepL cells resembled that of hepatic endoderm, not
mature polygonal hepatocytes. At later stages, cells with
fibroblastic morphology died out while the cultures be-
came homogeneously formed by epithelial cells. We ex-
tracted RNA at day 14 to check if any plate had initiated
the hepatic differentiation program by measuring the ex-
pression of early hepatic markers Alb, Foxa1, Foxa2endo,
Tat, Slc10a1 (Ntcp), and Cyp7a1 (Fig. 1b). The combin-
ation of hepatic factors and OSKM supplemented with
the incubation of the transduced cells in HCM I showed
the best induced hepatic-gene expression (Additional file 1:
Figure S1B). Concomitantly, we did not detect expression
of Nanog and Lin28, confirming that infected cells did not
commit to the pluripotent fate (Fig. 1c). It is noteworthy
that retroviral combinations that did not include OSK/M
became quiescent and did not allow us to obtain frozen cel-
lular stocks. Thus, the presence of reprogramming factors
in the cocktail not only seems to improve the expression of
early hepatic markers, but also provides the proliferative
stimuli necessary for both reprogramming and cell growth
[26]. We selected the retroviral cocktail containing OSKM
with Gata4, Foxa2, Hnf4a, Hhex, Hnf1a, and Hnf6a for fu-
ture improvement of our differentiation protocol.
iHepL cells repress fibroblast markers and activate the
hepatic transcriptional program
Having successfully initiated the earliest hepatocyte re-
programming of MEF, we added an additional step in
order to improve our differentiation protocol (Fig. 1d).
Briefly, infected MEF were cultured in DMEMc for
3 days and then cells were switched to HCM I and
maintained for 18 days. At this stage, cells could be
maintained in culture at low density for several passages
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in HCM I media without any further differentiation (ex-
pansion phase), frozen in liquid nitrogen, or continue to
the final differentiation process. The efficiency of con-
version to early iHepL was approximately 0.06 %. To in-
duce terminal differentiation, cells (frozen or in culture)
were cultured at high confluence in HMC II media for 6
additional days. Early iHepL cells (after 21 days) were
highly proliferative in culture (Fig. 1e), probably due to
the expression of Myc (Fig. 1f ).
iHepL cells displayed a typical epithelial morph-
ology, showing a significant increase in the epithelial
markers Cdh1 and Ocln (Fig. 2a and d) and downreg-
ulation of the mesenchymal markers Snail1, Zeb1,
and Thy1(Fig. 2b).
Our protocol is not favorable for the establishment or
maintenance of pluripotency since we do not include
LIF in our reprogramming media. However, to exclude
the possibility that we carried over cells from colonies in
an intermediate reprogramming state, we measured the
expression levels of critical genes in the pluripotent tran-
scriptional network. We could not detect expression of
Nanog, Lin28, endogenous Oct4, or endogenous Sox2 by
qRT-PCR (Fig. 2c and Additional file 1: Figure S2A).
Moreover, exogenous Oct4 and Sox2 could not be de-
tected. Absence of Nanog and Ssea1 were confirmed by
immunocytochemistry and flow cytometry (Fig. 2d and
Additional file 1: Figure S2B).
Next, we examined endogenous hepatic transcription
network activation in iHepL cells. The qRT-PCR results
showed that the endogenous expression of Foxa1, Foxa2,
Foxa3, Cebpa, and Hhex were activated (Fig. 2e). Hnf4a, a
core transcription factor involved in the hepatic cross-
regulatory network and hepatocyte maturation [27], was
endogenously expressed at high levels. iHepL cells signifi-
cantly expressed genes such as Afp, Slc4a2, MaoB, Fmo1,
or Nat2. In contrast, the expression of genes characteristic
of mature hepatocytes was not homogeneous. While
Cyp7a1, Cyp2c39, or Ugt1a1 were expressed at significant
levels compared to primary cultured mouse hepatocytes,
other Cyp450 isozymes, Tat, Slc10a1 (Ntcp), Aat1, or Otc
were absent or hardly detectable. Hepatic-specific micro-
RNA miR122, highly and specifically expressed during
embryonic development of the liver [28], was expressed at
hepatocyte-specific levels in iHepL cells.
Immunofluorescence analysis revealed high expression
of multiple transcription factors (Hnf4, Hnf6, Hnf1, and
Sox9) as well as hepatic enzymes such as Glucokinase
(Gck), Glycogen synthase 2 (Gys2), and Albumin
(Fig. 3a). The percentage of iHepL cells expressing those
proteins as well as Ugt1a1 was between 60 and 90 %,
showing a striking homogeneity of the cells (Fig. 3b). In
fact, when individual iHepL cells were isolated and
expanded, they displayed similar expression patterns
(Additional file 1: Figure S3A). Interestingly, an average
99.4 ± 0.6 % of live iHepL cells were GFP-positive
(Additional file 1: Figure S3B).
iHepL cells perform basic hepatocyte-specific functions
Having successfully proven the expression of the hepatic
transcriptional program, we explored the ability of
iHepL cells to perform specific hepatocyte tasks. Indocy-
anine green uptake, a clinically used test for basic liver
function [29], was performed by most of the iHepL cells
(Fig. 4a). PAS staining of the adherent cultures revealed
that most of the cells stored glycogen and depleted it in
response to glucagon (Fig. 4a and b). Moreover, when
iHepL cells grown in complete media were changed to
media without glucose, glycogen stores were also de-
pleted (Fig. 4c). However, glycogen depletion was not
followed by a significant secretion of glucose into the
media, a role that depends on the activity of glucose-6-
phosphatase. Similarly, iHepL cells could not generate
urea when cells were incubated with ammonium chlor-
ide as a nitrogen source, an activity that relies on an ac-
tive urea cycle (data not shown).
Hepatic Cyp450 are major enzymes accounting for drug
detoxification expressed at high levels only in fully mature
postnatal hepatocytes. iHepL cells expressed some phase I
and phase II drug metabolic genes (Cyp2c39, Ugt1a1,
Fmo1, and Nat2) at the mRNA level (Fig. 2a). To evaluate
the acquisition of drug-metabolizing capabilities, we incu-
bated iHepL cells with a cocktail of Cyp450 substrates
[23] and monitored the formation of the metabolites by
ultra-performance liquid chromatography-tandem mass
spectrometry. iHepL cells were able to metabolize
phenacetin, bufuralol, diclofenac, midazolam, mephe-
nytoin, and bupropion, but the rate was between 30-
and 500-fold lower than 24-h primary cultured mouse
(See figure on previous page.)
Fig. 1 Conversion of MEF into hepatic-like cells. a Phase contrast photographs of mock-infected mouse embryonic fibroblasts (MEF), an epithelial
colony (7 days after infection; Colony), and early-stage hepatic progenitor-like (iHepL) cells. b Expression levels of Alb, Foxa1, Foxa2endo, Tat, Slc10a1
(Ntcp), and Cyp7a1 mRNA in pooled MEF at 14 days post-infection grown under the indicated conditions. Mock-infected MEF grown in DMEMc
were used as negative control. OSKM: Oct4, Sox2, Klf4, Myc; OSK: Oct4, Sox2, Klf4. Data are represented as mean ± SD (n = 3). c Expression levels of
Nanog and Lin28 mRNA as described in (b). MEF infected with OSKM (iPSC) were used as a positive control. d Timeline showing the improved
experimental procedure for direct induction of hepatic-like cells. e Growth curve of iHepL cells at day 21. Exponential growth accurately described
the data (R2 above 0.99). The population-averaged doubling time (Dt) was calculated from these fits. Data are represented as mean ± SD (n = 3).
f Representative fluorescence images of HepG2 and iHepL cells immunostained for proliferative markers phospho-Histone H3 (pH3), Ki67, and
Myc. Nuclei were stained with DAPI
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hepatocytes (Additional file 1: Figure S4). Remarkably,
UDP-glucuronosyl transferase activity in iHepL cells
(measured by glucuronidation of β-estradiol) was in
the range of primary cultured hepatocytes.
The absence of mature hepatic functions prompted
the investigation of whether iHepL cells were, in fact,
hepatic progenitors or immature hepatocytes. Hepatic
progenitors are bipotential, i.e., they can differentiate to-
wards hepatocytes or cholangiocytes. Previous studies
have shown that hepatic progenitors isolated from adult
liver (Lgr5-positive [30], Foxl1-positive [15] and M +
133 + 26– cells [31]) or obtained by fibroblast repro-
gramming (iHepSC [9]) are enriched in duct-specific
markers. Analysis by qRT-PCR confirmed that our
iHepL cells express high mRNA levels of multiple duct
cell markers (Fig. 4d). Moreover, iHepL cells also
expressed Cd24a and Foxl1, specific lineage markers of
bipotential hepatic progenitors in the adult liver (Fig. 4e).
Lgr5 expression was not homogeneous, being only
present in specific cells, even in cells expanded from a
single cell-colony (Fig. 4f and Additional file 1: Figure
S5). We concluded that iHepL cells do not functionally
resemble mature hepatocytes, but bipotential hepatic
progenitor cells.
iHepL cells colonize the liver parenchyma and ducts of
hepatectomized mouse after hepatic irradiation
In order to test the bipotentiality of iHepL cells in vivo,
we performed intrasplenic transplantation into five mice
subjected to liver irradiation and partial hepatectomy.
Liver irradiation limits the proliferation of resident hepa-
tocytes while hindering the immune response of the
acceptor mice [32]. Partial hepatectomy provides the
needed mitotic inducer in the donor hepatocytes. In
order to track iHepL cells in vivo, we took advantage of
maintained GFP expression from the bicistronic
pMIGR1 retroviral vector (GFP-positive cells; Fig. 3a
and Additional file 1: Figure S3).
All five mice transplanted with iHepL survived and
show different degrees of colonization, estimated to be
between 5 % and 25 % based on GFP-positivity in serial
sections (Additional file 1: Figure S6). Of note, our dam-
age model provides no stimulus for expansion of the cells
after engraftment, limiting the degree of colonization.
Fluorescence above the general background was detected
in big clusters, small clusters, and sometimes 1-3 isolated
iHepL cells infiltrating into the surrounding mouse liver
parenchyma (Fig. 5a). Contribution of iHepL cells to the
bile duct network was limited and, commonly, big clusters
of GFP-positive cells surrounding GFP-negative cells
forming multiple duct structures could be observed
(Fig. 5a). Immunostaining with Hnf4a, Hnf1a, Albumin,
Haptoglobin, and Glucokinase antibodies confirmed the
differentiation of iHepL cells toward the hepatocyte
lineage (Fig. 5b). GFP-positive iHepL-derived cells fully in-
tegrated into the E-cadherin network of the liver paren-
chyma. Binucleation, a hallmark of hepatocyte maturation,
was also commonly detected in GFP-positive cells. IHepL-
derived cholangiocytes were identified by immunostaining
with Sox9 and Ck17-19 antibodies (Fig. 5b). Approxi-
mately 2 % of iHepL-derived cholangiocytes were counted.
Thus, iHepL cells display characteristics of bipotential
hepatic cells and are able to differentiate into hepatocytes
or cholangiocytes in vivo. Most of the iHepL cells in
recipient mouse livers had stopped proliferation, simi-
lar to hepatocytes in wild-type mice [33], as assessed
by the expression of the proliferation marker Ki67
and phospho-Histone H3 (Additional file 1: Figure S6
and data not shown).
In hematoxylin-eosin stained sections, no major ab-
normalities were observed in most of the mice, except
for a dysplastic cell mass found in one of the livers. Nu-
clei within the cell mass were very heterogeneous in size
and shape, and cells infiltrated to the liver parenchyma
(eosinophilic, orange staining), suggesting a cell malig-
nancy. The presence of dysplasia in bile cholangioles
suggest that the origin of the tumor might be the bile
duct tree (Fig. 6a). It is noteworthy that the cells within
the tumor were GFP-negative (Fig. 6b). Tumor cells
were highly proliferative based on phospho-Histone H3
(pH3) immunostaining; however, GFP-positive cells
present in the surrounding tissue were not proliferating.
Tumor cells were also negative for E-cadherin. In fact,
an E-cadherin staining pattern was only maintained in
GFP-positive cells found at the interface between normal
and tumorigenic tissue. In conclusion, the absence of
mature ectodermal, mesodermal, and endodermal
structures, the lack of encapsulation, and the high
(See figure on previous page.)
Fig. 2 iHepL cells upregulate hepatic mRNA. Total RNA was extracted from hepatic progenitor-like (iHepL) cells, mouse embryonic fibroblasts (MEF),
primary cultured mouse hepatocytes (PMH) and induced pluripotent stem cells (iPSC). Expression levels of epithelial markers (a), mesenchymal markers
(b), and pluripotency markers (c) were assessed by qRT-PCR and plotted as relative gene expression. Data are represented as mean ± SD from iHepL
cells (n = 6; three infections and two biological replicates each), MEF (n = 3), PMH (n = 4), and iPSC (n = 3). Student’s t test was performed between
iHepL and the other groups; *p < 0.05; **p < 0.01. d Representative fluorescence images of iHepL, mouse embryonic stem cells (mESC), and MEF
immunostained for E-cadherin and the pluripotency markers Nanog and Ssea-1. Nuclei were stained with DAPI. e mRNA levels of multiple hepatic
markers were measured by qRT-PCR in total RNA extracted from MEF and iHepL cells. Data are represented as mean ± SD from iHepL cells (n = 6; three
infections and two biological replicates each), MEF (n = 3), and PMH (n = 4). Student’s t test was performed between iHepL and the other groups;
*p < 0.05; **p < 0.01
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proliferation rate of the cells exclude that tumor cells
were a teratoma.
The absence of GFP in the tumor cells did not clarify
the cellular origin of the tumor. In order to investigate
whether the tumor originated from our iHepL cells, we
ran conventional tumorigenic analysis by subcutaneous
injection in four mice. After 45 days, all the animals
developed a solid dysplastic cell aggregate mainly com-
posed of highly proliferative undifferentiated cells
(Fig. 6c). Again, cells were GFP-negative, recapitulating
the features of the cell mass found in one of the livers.
We could not detect any evidence of mature ectodermal,
mesodermal, or endodermal structures (most frequently
skin, hair follicles, sebaceous and sweat glands, cartilage,
adipose tissue, and glia) characteristic of teratomas typ-
ically originated from embryonic stem cell implanted in
nude mice. To get a deeper insight into the tumor cell
origin, we performed a comparison of transgene copy
number in genomic DNA isolated from tumors and iHepL
(Fig. 6d). Fifty percent or more of the tumors contain the
same copy number for GFP, Hnf6aexo, Hhexexo, Oct4exo,
Sox2exo, and Klf4exo than iHepL cells (Additional file 1:
Table S6). Moreover, iHepL and tumor cells do not con-
tain the transgenes for Oct4 and Sox2 in their genomic
DNA, confirming the lack of exogenous expression. These
analyses exclude the possibility that partially pluripotent
iPSC are the origin of tumors and a possible transition
through a transient pluripotent state before committing to
the hepatic lineage.
Discussion
Cell reprogramming technology holds great promise as a
potential strategy in cell replacement therapies. However,
the possible tumorigenic potential of reprogrammed cells
has also raised concerns about their clinical use. Several
authors have reported the generation of iHep cells without
tumorigenic features [5, 7, 9]. Here, we report the direct
lineage conversion into hepatic progenitor-like cells
(iHepL) with the use of pluripotency factors which show
tumorigenicity when transplanted in vivo. Tumor cells
and iHepL cells do not contain transgenes for Oct4 or
Sox2, pointing at Klf4 and Myc as probably responsible for
induced tumorigenicity and excluding rare partially pluri-
potent cells as responsible for tumor formation. Our work
highlights that the risk of tumorigenesis in direct lineage
conversion using pluripotency factors should be examined
with the same rigor as in the case of iPSC-derived lineage
cells. On the other hand, recent reports have indicated
that the inclusion of pluripotent transcription factors
during direct somatic lineage conversion cause cells
to go through a transient pluripotent state during
cardiac and neural somatic cell transdifferentiation
[34, 35]. The absence of Oct4 and Sox2 transgenes in
iHepL genomic DNA suggests that MEF directly com-
mitted into the hepatocyte lineage, since Oct4 and
Sox2 are essential factors for pluripotent reprogram-
ming [18]. Moreover, a recent report has found that
Klf4 and Myc dramatically accelerate direct hepatic
reprogramming, probably by promotion of a
mesenchymal-to-epithelial transition [36].
iHepL cells are able to perform basic hepatic functions
such as glycogen storage or indocyanine green uptake,
but fail to perform functions characteristic of mature
hepatocytes such as urea cycle or high Cyp450-
dependent drug metabolism. Knowing this, it is striking
that the mRNA level of Cyp2c39 in iHepL cells is 43 %
of that of 24-h primary hepatocytes in culture, while the
actual activity is 75-fold lower (0.01 %). Primary hepato-
cytes in culture lose the transcription of genes charac-
teristic of mature hepatocytes within the first 2–4 h
[37]. In fact, when we measured the expression of
Cyp2c39 in mouse hepatocytes cultured for 4, 24, 48,
and 72 h the levels dropped 97 % in the initial 24 h com-
pared to mouse liver (Additional file 1: Figure S7A).
However, Cyp2c39 activities remained fairly stable dur-
ing the first 24–48 h (Additional file 1: Figure S7B). This
is probably due to the longer protein half-life compared
to its mRNA [38].
Recently, the direct conversion of fibroblasts into
hepatic-progenitor cells (iHepSC) able to differentiate in
vivo into hepatocytes and cholangiocytes was reported
[9]. iHepSC and hepatic progenitor cells isolated from
adult livers (Lgr5-positive cells [30] and Foxl1-positive
cells [15]) shared the expression of multiple markers, in-
cluding genes specifically expressed in duct/cholangio-
cytes. iHepL cells display high levels of duct cell markers
together with immature hepatocyte markers. The pro-
genitor nature of our iHepL cells is endorsed by the ele-
vated expression of Foxl1 and Cd24a mRNA (20-fold
and 85-fold compared to whole liver) and Lgr5 protein,
(See figure on previous page.)
Fig. 3 iHepL cells express hepatic genes. a Representative fluorescence images of HepG2, mouse embryonic fibroblasts (MEF), and hepatic
progenitor-like (iHepL) cells immunostained with antibodies against multiple proteins. No differences were observed between the iHepL pool or
clones 2, 6, and 15 (Additional file 1: Figure S3). Nuclei were stained with DAPI. b Representative fluorescence images at low magnification of MEF
and iHepL cells immunostained for Albumin (Alb), Ugt1a1, Glucokinase (Gck), and Glycogen synthase 2 (Gys2). Nuclei were stained with DAPI. Bar
diagrams in the right panel show the signal intensity distribution (strong, medium, or weak) in MEF or iHepL cells by the high content screening
imaging station Scan® from Olympus. Data are represented as mean ± SD. Student’s t test was performed between iHepL and MEF. and statistical
significance was p < 0.01 in all cases
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which are markers for bipotential progenitor cells iso-
lated from adult liver [14, 15].
Progenitor features of iHepL cells were confirmed in
transplantation studies. Engrafted iHepL cells were iden-
tified by GFP expression, since directly converted iHep
cells do not completely silence the retroviral gene [5, 7].
iHepL cells differentiated into hepatocytes and cholan-
giocytes in vivo. The presence of iHepL-derived hepato-
cytes (parenchyma) and cholangiocytes (bile ducts)
differs significantly. While we estimated an engraftment
of 5–25 % in the liver parenchyma (GFP-positive hepato-
cytes vs total), the engraftment in bile ducts was around
2 %. This result suggests that iHepL cell bipotentiality is
biased towards the hepatocyte lineage, or that our in
vivo model favors regeneration of the duct network with
resident cholangiocytes/progenitors. Previous reports of
iHep cells derived from MEF have never found any
evidence of cell fusion when transplanted into mouse
[5, 7, 9]. Nevertheless, Y chromosome staining in male
livers transplanted with female iHepL cells would be ne-
cessary to exclude the possibility of cell fusion.
Cell transplantation studies using the fumarylacetoace-
tate hydrolase-deficient mice (Fah–/–) favors the prolif-





Fig. 4 iHepL perform basal hepatocyte functions and express markers of bipotential hepatic progenitors. a Indocyanine green and periodic acid-Schiff
(PAS) staining of hepatic progenitor-like (iHepL) cells and mouse embryonic fibroblasts (MEF). b PAS staining of iHepL treated with glucagon for 0, 1.5, 3,
and 6 h. c PAS staining of iHepL cultured in glucose-free medium for 0, 3, and 6 h. d, e Total mRNA was extracted from MEF or iHepL cells and the
expression of typical cholangiocyte (d) and hepatic-progenitor (e) markers was assessed by qRT-PCR and represented as relative gene expression
normalized to total mouse liver. Data are represented as mean ± SD from iHepL cells (n= 6; three infections and two biological replicates each) and
MEF (n = 3). Student’s t test was performed between iHepL and the other groups and statistical significance was p < 0.001 in all cases. f Representative
fluorescence images of iHepL, HepG2, and MEF immunostained for Lgr5 and Hnf1a. No differences were observed between the iHepL pool or clones 2,
6, and 15 (Additional file 1: Figure S5). Nuclei were stained with DAPI
Serrano et al. Stem Cell Research & Therapy  (2016) 7:96 Page 11 of 15
parenchyma but not cholangiocytes [9]. We have used
two-thirds hepatectomy and irradiation as an in vivo
model since this provides an optimal niche for parenchy-
mal (hepatocyte) and non-parenchymal (cholangiocyte)
cell engraftment [39, 40]. Moreover, the engraftment of
the exogenous cells in the irradiated liver lobe consti-
tutes by itself a rescued experiment because this lobe
would atrophy if no exogenous cells are supplied, while
a
b
Fig. 5 Repopulation of the liver of hepatectomized mouse after hepatic irradiation. Approximately 106 iHepL cells (GFP-positive) were
transplanted into partial hepatectomized and hepatic irradiated mice (n = 5). a Low magnification representative fluorescent images
showing engraftment of iHepL cells in the mouse liver after 3 weeks. b Co-immunofluorescence staining of GFP with several hepatocyte
and cholangiocyte markers. Nuclei were counterstained with DAPI (blue). Red blood cell auto-fluorescence is observed in some images.
GFP green fluorescent protein




Fig. 6 Tumorigenicity associated with iHepL cells. a Hematoxylin and eosin (H&E) staining of a liver section showing a cell mass after hepatic progenitor-like (iHepL)
cell transplantation in the spleen. Tumor cells (black arrow) are less eosinophilic and the nuclei are abnormal in size and shape when compared to hepatocytes
(green arrow). b Cells within the tumor that do not express green fluorescent protein (GFP) proliferated intensely and lost the characteristic E-cadherin staining. A
white dotted linemarking the borders of the cell mass is displayed. Co-labeling of GFP and phospho-Histone H3 (pH3) is not observed. c iHepL cells (1.5 ×
106/injection) in 150 μl DPBSwere implanted subcutaneously in the right flank region of mice (n = 5). Upon sacrifice, primary tumors were removed,
formalin-fixed, and histologically evaluated by H&E staining and immunostainingwith antibodies against pH3, Ki67, and Hnf4. Nuclei were counterstained
with DAPI (blue). d Relative gene copy number analysis. Genomic DNA isolated from iHepL cells in culture, embedded tumors, and embedded control
liver mouse tissue was analyzed by qPCR using primers specific for intron 1 and intron 2 of Ccnd1 gene, GFP, and fragments corresponding to lentiviral
vectors pMIGR1-Hnf1a (HNF1aexo), pMIGR1-Hnf6a (Hnf6aexo), pMIGR1-Hhex (Hhexexo), pMSx-Oct4 (Oct4exo), pMXs-Sox2 (Sox2exo), pMXs-Klf4 (Klf4exo), and
pMXs-cMyc (cMycexo). Data were normalized to the level of Intron 1 of Ccnd1 gene; a fragment of intron 2 from Ccnd1 genewas used as a secondary
normalization control. Then values for each sample were normalized to the value for iHepL cells. *p < 0.05; **p < 0.005 (compared to iHepL cells)
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there is no proliferation/survival advantage to engrafted
cells, limiting the extension of liver colonization.
One out of five transplanted mice developed a GFP-
negative cell mass juxtaposed to the liver. In addition,
when cells were subcutaneously injected in nude mice,
they generated dysplastic cell masses composed of GFP-
negative, undifferentiated, highly proliferative cells.
Although a combination of qRT-PCR, immunocyto-
chemistry, and flow cytometer analysis did not detect
the expression of Oct4, Sox2, Nanog, or Ssea1, it is still
feasible that these cell masses could be teratomas origin-
ating from rare GFP-negative partially pluripotent cells
contaminating iHepL cells. However, the solid nature of
the cell mass (not encapsulated, not cyst-like), the ab-
sence of any mature structure (endodermal, mesodermal,
or ectodermal), and the high proliferation rate of the
cells lets us conclude that it is not a teratoma but a
tumor malignancy. Still, tumors could have been origi-
nated by rare tumorigenic GFP-negative cells contamin-
ating our iHepL cells. Again, we favor an alternative
hypothesis, since 50 % or more of the tumors contain
the same copy number for GFP, Hnf6aexo, Hhexexo,
Oct4exo, Sox2exo, and Klf4exo as iHepL cells. All tumors
contain three-fold the number of copies of the Myc
transgene. If rare tumorigenic GFP-negative Mychigh cells
were contaminating our iHepL cultures, GFP-positive
cells would dilute out after multiple cell passes, some-
thing we never observed (Additional file 1: Figure S3B
depicts the analysis of p20 iHepL).
Based on the fact that tumor cells were GFP-negative,
but contain the same number of copies of the GFP
transgene, we hypothesize that cell masses are not tera-
tomas originating from partially pluripotent cells, but
that malignant tumors originated from GFP-positive
iHepL cells that lost expression of hepatic factors (co-
expressed with GFP from a bicistronic cassette) trigger-
ing the tumorigenicity of Myc [41].
Conclusions
Our study highlights the dangers of using pluripo-
tency factors, in particular Klf4 and Myc, in cell
reprogramming due to their intrinsic oncogenic prop-
erties. The expression of hepatic cell fate mediators
triggered reprogramming into cells with gene expression
profiles similar to that of other hepatic-progenitor cells
isolated from adult liver, able to differentiate in vivo
into hepatocytes and cholangiocytes. However, we
obtained evidence that silencing of hepatic cell fate
mediators such as Hhex and/or Hnf1a result in
tumorigenicity. Thus, extensive tumorigenic studies
are essential in any reprogramming endeavor even if
no tumors are detected in the in vivo engraftment
experiments.
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